Galimedix Therapeutics, Inc. |

Galimedix Therapeutics, Inc.

Galimedix is a Phase 2-ready biotech developing cutting-edge orally and topically administered therapies to treat major neurodegenerative diseases where amyloid beta (Aβ) plays a known role. Galimedix’s initial areas of focus are dry acute macular degeneration (dAMD), glaucoma and Alzheimer’s disease. With a potentially game-changing approach, Galimedix seeks to target the underlying cause of disease, preventing the formation of all possible toxic Aβ oligomers while removing existing ones, resulting in neuroprotection and slowing/stopping disease progression. The Company has two main compounds – GAL-101 and GAL-201, which are designed to be more effective, have fewer side effects and be easier to use than current treatments. A Phase 2 trial in dAMD is expected to start in 2024.

Field of Activity	Current areas of focus are dAMD, glaucoma and Alzheimer’s disease.
Ownership Structure and Financing	Private, seeking additional investors
Partners	Théa Open Innovation – development & commercialization of GAL-101 for dAMD, glaucoma & other ophthalmic indications in Europe, the Americas, the Middle East & Africa Seeking partners for GAL-101 – ophthalmology, Greater China, Asia/Pacifi c for GAL-201 – Alzheimer‘s disease, global
Technology	Stopping neurodegeneration at its source – small molecules designed to address Aβ early, preventing the formation of toxic Aβ oligomers that lead to disease

Products/Services	GAL-101 (eye drops) – Phase 2 ready – dAMD, glaucoma GAL-101 (oral) – Preclinical – dAMD, glaucoma GAL-201 (oral) – Preclinical – Alzheimer’s disease
Unique Selling Point	Prevents formation of all toxic Aβ species Aβ-detoxifying activity long-lasting post 1 application Easy to produce, stable, low COGs Patient-friendly administration

Contact

Alexander Gebauer, M.D., Ph.D. Co-founder, Executive Chairman

Address	3704 Calvend Lane Kensington, MD 20895 USA
Telephone/ Fax	+972-4-9905139
E-Mail	info@galimedix.com
Web Address	https://www.galimedix.com/
Social Media	LinkedIn
Date of Incorporation/Number of Employees	2018/7

ARTIKEL ZU DIESEN SCHLAGWORTEN